ADAR1 Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

Key Points

• ADAR1 Capital Management acquired 730,649 Sarepta Therapeutics shares worth approximately $13.13 million, representing a 0.69% stake. Institutional investors collectively own 86.68% of SRPT.
• Sarepta shares recently traded at $18.92, up 4.4%, with a market capitalization of about $2 billion and a 52-week range of $14.68 to $25.32.
• The company beat quarterly earnings and revenue expectations, reporting $0.64 EPS and $401.25 million in revenue, though revenue fell 34.3% year over year. Analysts maintain a consensus Hold rating with an average price target of $25.06.

ADAR1 Capital Management LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 730,649 shares of the biotechnology company's stock, valued at approximately $13,130,000. ADAR1 Capital Management LLC owned 0.69% of Sarepta Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of SRPT. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics in the third quarter valued at approximately $25,000. Meeder Asset Management Inc. acquired a new position in Sarepta Therapeutics during the second quarter valued at approximately $27,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Allworth Financial LP lifted its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,721 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 4.4%

NASDAQ SRPT opened at $18.92 on Wednesday. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -6.52, a price-to-earnings-growth ratio of 0.27 and a beta of 0.23. Sarepta Therapeutics, Inc. has a twelve month low of $14.68 and a twelve month high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The business's fifty day moving average is $17.53 and its 200 day moving average is $18.26.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.42. The business had revenue of $401.25 million during the quarter, compared to analysts' expectations of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business's revenue for the quarter was down 34.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 EPS. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SRPT. Weiss Ratings lowered Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research note on Wednesday, August 19th. Wall Street Zen downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Piper Sandler reduced their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a research note on Thursday, July 9th. Zacks Research upgraded Sarepta Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Finally, Wolfe Research raised Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $25.06.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source